iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

NCT ID: NCT05416086

Last Updated: 2023-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-03

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, single-arm, multi-center study designed to collect real world safety and performance data of the Adagio Medical iCLAS Cryoablation System in the treatment of drug refractory, recurrent, symptomatic, Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation (PsAF), and Atrial Flutter (AFL).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Post-Market Clinical Follow-up (PMCF) study continues collecting additional information about the Adagio Medical iCLAS™ Cryoablation System in real world clinical settings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Atrial Flutter Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iCLAS Cryoablation arm

all subjects will receive a cryoablation procedure with the iCLAS System and be followed up for 12-month

Group Type OTHER

cryoablation procedure using the iCLAS Cryoablation System

Intervention Type DEVICE

all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cryoablation procedure using the iCLAS Cryoablation System

all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is ≥ 18 years of age
* Planned ablation procedure according to the indication for use of the commercially available Adagio iCLAS™ Cryoablation System
* Subject willing to comply with study requirements and give informed consent.

Exclusion Criteria

* In the opinion of the Investigator, any known contraindication to an atrial ablation procedure with the Adagio iCLAS™ Cryoablation System as indicated in the device Instructions For Use (IFU).
* Subject is enrolled in a study that has not been approved for concurrent enrollment by the sponsor.
* Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than one year, extensive travel away from the research center)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Adagio Medical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Onze-Lieve-Vrouw Hospital Aalst (OLV)

Aalst, , Belgium

Site Status RECRUITING

Universitatsklinikum Erlangen

Erlangen, , Germany

Site Status RECRUITING

St. Antonius Ziekenhuis

Nieuwegein, , Netherlands

Site Status RECRUITING

Erasmus MC

Rotterdam, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium Germany Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nabil M Jubran

Role: CONTACT

(949) 348-1188

Doug Kurschinski

Role: CONTACT

(949) 348-1188

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tom de Potter, MD

Role: primary

Lars Anneken, MD

Role: primary

Lucas Boersma, MD

Role: primary

Tamas Szili-Torok, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CS-086

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FREEZE Cohort Study
NCT01360008 COMPLETED
Medtronic Terminate AF Study
NCT03546374 RECRUITING NA